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Abstract
Oncolytic viruses are known as genetically engineered viruses or ones that can be found
in nature, that are used to selectively reproduce in cancer cells and kill them without harming the
normal and healthy cells. Oncolytic viruses have been considered an effective form of
immunotherapy and offer a new approach for cancer treatment. Only one oncolytic virus has
been approved by the Food and Drug Administration (FDA) in the USA, which is T-Vec
(talimogene laherparepvec). This is a second-generation oncolytic herpes simplex virus type 1
(HSV-1). Another oncolytic virus has been approved only in China in 2005, which is called
Oncorine. It is an E1B-deleted adenovirus, which is used for head and neck cancer and
esophagus cancer (Fukuhara, Ino, Todo, 2016). This paper will demonstrate the clinical
effectiveness of oncolytic viruses and how they have proven to help with cancer immunotherapy.

I.

Introduction
A. Background
Oncolytic viruses have been proven to be effective when it comes to
immunotherapy, as they are able to properly induce host antitumor immunity.
There are a variety of viruses that have been tested as potential oncolytic viruses
such as poxvirus, herpesvirus, picornavirus, etc. Each of these viruses uses
multiple cell surface receptors to gain entry. Oncolytic viruses are known to
mediate antitumor activity through selective replication and lysis within infected
cancer cells and through induction of host antitumor immunity (Kohlhapp and
Kaufman, 2016).
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B. History
Using viruses as a form of cancer therapy is an old concept and has been
around for more than 100 years. In 1912, Italian doctors had discovered a rabies
vaccine that was shown to cause cervical cancer regression, which is how the
concept of oncolytic virus therapy emerged (Cao, He, Sun, Chen, Wan, Xu, Feng,
Li, Chen, and Xiong, 2020). In the 1950’s and 1970’s, there were a lot more
clinical trials conducted that utilized the wild-type viruses for treating tumors,
however, the issue was that it was not possible to control the pathogenicity of the
virus. It was in the 1980’s when oncolytic viruses began to gain more popularity
due to the increased advancement in genetic engineering technology, which
allowed the genome of the virus to be altered. There was another notable time in
2005 when people were starting to understand that the value of viruses in cancer
therapy is in immunotherapy (Gromeier, 2018). Nowadays, viruses are known to
effectively mediate immunotherapy.

C. Function of Mechanism
Oncolytic viruses function in a way where they self-replicate so that they
can destroy the host in cancer cells. They hijack the cell’s protein synthesis and
can mediate the production of viral particles. Due to this, the infected host cells
lyse, and sub viruses are spread so that they are able to infect other cells. The
tumor growth must inhibit the immune system.
These viruses have strong effects on the immune cells entering the tumor
tissue, which can change the microenvironment of the tumor. Tumor cells that are
infected with the virus express danger signals, for example cytokines, which then
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prompt the immune cells outside the tumor to integrate into the tumor and activate
non-specific immune cells. A large amount of tumor proteins are released by
tumor cells that are lysed by oncolytic viruses, which can be phagocytized by
non-specific immune cells. Additionally, tumor-specific antigens are expressed by
antigen presenting cells, which can then induce T cells and direct them to attack
the uninfected tumor cells (Bai, Hui, Du, Su, 2019).
Viruses contain many different characteristics that can be exploited such
as being able to replicate in the host cell, which can allow for self-amplification
and make it easier so that every target cell is infected at the time of the first
treatment. Another beneficial characteristic is the specificity for a certain type of
cell/cell receptor, for example, a neural or epithelial cell. The virus could interact
differently with healthy cells as compared to cancerous cells, however, the host
response to infections deals with humoral and cell-mediated processes with the
host response to malignant cells (Sze, Reid, Rose, 2013).
From the article Oncolytic Virotherapy, Dr. Sze, Dr. Reid, and Dr. Rose
feature a diagram that demonstrates the mechanism of how an oncolytic virus
attacks a cancerous cell (figure 1). It is shown that an oncolytic virus (black
hexagon) attacks the cancerous cell (a). The virus enters the cancer cell with ease
due to specificity for a tumor-related cell surface receptor or antigen. After the
malignant cell is infected, the cancerous genetic material is propagated and
unchecked replication of the oncolytic virus is allowed (b), due to the cell’s
permissive nature. An infection of the healthy and normal cell (f) is unsuccessful
due to the cell’s ability to identify and kill any abnormal genetic material. Now,
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the infected cell (b) will make viral proteins that are antigenic and can notify the
immune system. Additionally, if the virus is genetically equipped, the cell can
produce cytokines in order to active the immune system. Since the cancer cell is
infected, it becomes swamped by the viral infection and therefore, lyses. This in
turn, causes the cancer cell to release new viral particles so that it can infect the
neighboring malignant cells (c). The new viral and tumor-related antigens
released due to the lysis can be recognized by the immune system and then
attacked, which is represented by the lymphocyte (L). Viremia that is due to lysis
related activities can cause infection of distant metastases (d), which causes a shift
from a locoregional to systemic effect. The immune system is alerted and
activated due to the elevation of systemic cytokine levels and activated
leukocytes, which enhances the systemic effect. The immune system can also
develop memory and therefore, identify tumor antigens which can provide a more
durable defense against recurrent diseases.
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Figure 1: The mechanism of an oncolytic virus attacking a cancer cell
https://www.jvir.org/article/S1051-0443(13)01024-5/pdf

D. Delivery of Oncolytic Virus
There are many ways to administer oncolytic viruses into the body for
cancer immunotherapy. There are oral viral vaccines available for viruses such as
poliovirus, rabies virus, rotavirus, etc., however, taking the oral route results in
immunity being weaker than the parenteral route. The intravenous route is the
preferred method, and it is quite convenient. However, even though it is a
convenient route, there are disadvantages to this. The intravenous route does not
target cancer cells specifically. On top of this drawback, before the virus can even
reach the tumor, the antibodies that are made by the pre-existing immunity will
neutralize the virus. Therefore, the virus concentration might need to be increased,
but that means that it could also increase the inflammatory response, which is not
a desired outcome.
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Additionally, there are two other routes of radiation intervention: arterial
and tumor site administration. The intra-arterial method allows for the virus to be
selectively transported to the target cancer cells. Most importantly, this method
can avoid antibody neutralization because of limited blood volume and the target
organ.

II.

Literary Review
A. Positive Studies
There have been many types of cancers that have been targeted in clinical
trials when it comes to using oncolytic viruses. The most common tumors were
melanoma and GI cancers. There were 30 clinical trials for melanoma, which
accounted for 1000 patients. Meanwhile, there were 76 trials targeting patients with
GI cancer (Macedo, Miller, Haq, Kaufman, 2020). Figure 2 below shows the different
types of cancers that have been targeted in oncolytic virus clinical trials. Some other
common cancer types are head and neck cancer, breast and gynecological cancers,
genitourinary cancers, and sarcomas.

Figure 2: Cancer types targeted in oncolytic virus clinical trials
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7552841/
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There have been many studies that have demonstrated positive results when it
comes to oncolytic viruses in cancer therapy. In the journal Recent Advances of
Oncolytic Virus in Cancer Therapy (Mondal, Guo, He, Zhou, 2020), there were
multiple trials performed regarding the use of T-VEC. A phase I trial of T-VEC was
conducted which included 30 patients that were all affected with various types of
cancers, 9 of whom had refractory metastatic melanoma. Melanoma is cancer that
begins in the melanocytes, and it is classified as metastatic melanoma when it spreads
from the skin to other body parts. The T-VEC injection was administered
intratumorally, which led to remission in two patients, and they had no adverse
effects. This led to a phase II clinical trial that had stage III or IV melanoma. Out of
the 50 patients that were treated with T-VEC intratumorally, 8 patients had
accomplished a complete response, whereas 5 had a partial response. This led to a
phase III clinical trial, where there were 436 patients with stage IIIb, IIIc, and IV
unresectable melanoma. They were also treated with T-VEC and it was compared
with the recombinant GM-CSF (granulocyte-macrophage colony-stimulating factor).
For the 436 patients that were treated, the double response rate was much higher for
those treated with T-VEC as compared to GM-CSF. Overall, T-VEC showed
profound efficacy and there were not any adverse side effects except for fatigue,
chills, and pyrexia. The success of these trials, especially the third phase, played a
huge role in the FDA approval of T-VEC.
As mentioned earlier, oncorine is the first oncolytic adenovirus that was
approved by the China Food and Drug Administration Department (CFDA), which
was combined with chemotherapy in order to treat nasopharyngeal carcinoma in
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2005. There had been a phase III clinical trial that included patients with head and
neck squamous cell carcinoma and esophageal cell carcinoma. It was injected
intratumorally and H101 was combined with cisplatin and 5-fluorouracil (PF) or
adriamycin and 5-fluorouracil (AF) was compared with PF or AF treatment alone
(Mondal, Guo, He, Zhou, 2020). The safety and efficacy of this H101 injection was
observed in the trial. It served as a huge milestone as it was quite successful, and it
was launched in the market. After it was launched, there were additional clinical trials
that tested for oncorine regarding the four types of cancers. It turned out to be
successful for treating malignant plural effusion, which had a 38% complete recovery
(Mondal, Guo, He, Zhou, 2020).
There have also been studies proving how oncolytic viruses can help
potentiating prostate cancer immunotherapy. The microenvironment for prostate
cancer has plenty of immunosuppressive strategies that don’t allow the development
of antitumor immune responses. For example, lymphocytes (natural killer cells and
CD4+/CD8+) stay in an anergic state, therefore, they have the ability to express
inhibitory immune checkpoints. Some of these include programmed cell death and
cytotoxic T lymphocyte antigens. Antigen-presenting cells (macrophages and
dendritic cells) have little to no expression of major histocompatibility complex
(MHC) molecules. Additionally, the tumor expresses inhibitory immune checkpoint
receptors such as programmed cell death ligand 1 and V-type immunoglobulin
domain-containing suppressor of T cell activation, and harbors immunosuppressive
cells, myeloid derived suppressor cells, cytokines, metabolic products, and
prostaglandins (Lee and Gujar, 2018). This microenvironment immunosuppression
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inhibits the antitumor action of the immune cells. The role of oncolytic viruses kicks
in when they trigger an antiviral immune response, where type I interferons and proinflammatory cytokines are released. This allows for immune cells to do their job and
enter the tumor microenvironment. When oncolytic viruses kill the cancer cells, it
causes the release of unavailable tumor antigens, which are processed by antigenpresenting cells. Tumor-specific T cell immunity is then stimulated.
In addition to oncolytic viruses, other drugs can be used in combination with
them so that it can have a greater effect on the success of immunotherapy. Out of the
97 clinical trials reporting oncolytic viruses from 2000 to 2020, 61 trials were
conducted with oncolytic virus monotherapy, while 36 reported that oncolytic viruses
were given in combination with at least one other treatment (Macedo, Miller, Haq,
Kaufman, 2020). The most common drugs were cytotoxic chemotherapy agents and
chemotherapy prodrugs. Other treatments used in combination with oncolytic viruses
included radiation therapy, immunotherapy, and targeted therapy. The most common
chemotherapy agents used were paclitaxel and carboplatin which were often used
together. Additionally, some studies used cyclophosphamide which was used as
preconditioning chemotherapy to help enhance antitumor immune responses.
One of the most important combination therapies include CAR-T therapy with
oncolytic viruses. CAR-T (chimeric antigen receptor T) cell therapy has an in vitro
design, modification, and amplification of T cells that are taken from patients’ blood
to allow them to identify the surface antigens on tumor cells by the transduced CAR
structure on the surface of the T cell. After amplification has occurred, the CAR-T
cells are injected intravenously into the patient. Park et al performed a study that
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involved therapeutic combination using oncolytic viruses and CAR-T therapy. They
used an oncolytic chimeric orthopoxvirus that carries CD19t (OV19t) to make CD19t
at the cell surface.

B. Negative Studies
While there has been plenty of research supporting the use of oncolytic
viruses for cancer immunotherapy, there are also some limitations to this
approach. It is sometimes difficult to select the best route of administration for the
oncolytic virus. Usually, oncolytic viruses are ideal for direct IT injection,
however, this can limit the number and location of tumors that can be directly
treated (Macedo, Miller, Haq, Kaufman, 2020). Intravenous delivery can infect
metastatic lesions that are in multiple locations, however, administration of
oncolytic viruses into the circulation is limited by dilution in peripheral blood and
clearance by antibodies that already exist, as well as serum proteins. Therefore,
choosing which route to take for administration can be difficult and have
limitations. For example, when it comes to T-Vec, since HSV-1 spreads from cell
to cell, oncolytic HSV-1 is the most effective when it is administered
intralesionally and it may not work as well intravenously. However, it has been
proven in clinal trials in melanoma patients that local intralesional injections with
oncolytic HSV-1 can act on remote lesions via induction of systemic antitumor
immunity (Fukuhara, Ino, Todo, 2016).
Despite this drawback, there is another major concern when it comes to
oncolytic virus therapy. Researchers are concerned than the efficacy might be
reduced due to the circulating antibodies. For viruses that cause viremia, they are
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more likely to be vulnerable to neutralizing antibodies. Because of this, the
antitumor effect of intravenous administration could be limited to patients who
have had treatment done before.

III.

Discussion
A. Opinion
In my opinion, taking advantage of the mechanism of oncolytic viruses for
cancer immunotherapy is a beneficial and promising concept that has lots of
potential in the future. This mechanism allows innate and adaptive immune
responses to be generated, which can help produce an immune response against
tumor antigens and therefore, an immunological memory. While there can be
hurdles for oncolytic viruses, I believe with more extensive research, this can be a
strategic method to help fight cancer.

B. Future Direction for Research
As established, oncolytic viruses have proven to be beneficial in treating
cancer, however, there is still lot of room for improvement and future research
needed for this to be successful to the full extent. So far, there have been many
pre-clinical animal models, however, we are not quite sure how the anti-viral
responses can vary in humans. New research needs to be done to create viruses
that can correctly stimulate the immune system in hopes of achieving the desired
response, while at the same time, trying to avoid aberrant inflammation which
could be harmful for patients. Additionally, it has been proven in studies that the
true potential of oncolytic viruses is achieved when used in combination with
classical treatments and newer therapies. Therefore, future research should be
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conducted so that the oncolytic viruses can be as safe as possible and allowing
them to function properly in synergy with other compounds so that we can
achieve the full potential.
Regarding future research for treating prostate cancer with oncolytic
viruses, there will be a need of global and integrated consideration of
immunology and more clinical progression. Not only does there need to be more
research about the local tumor microenvironment, but there needs to be an
emphasis on metastatic sites due to the reason that prostate cancer can metastasize
to bones. Next, there needs to a better understanding of prostate cancer stem cells
due to immunosuppression and the implications of oncolytic virus treatments.
Immunosuppression related to prostate cancer is critical because a lot of
immunotherapies focus on correcting an impaired antitumor immunity, and also
because the immunosuppressive entities originating from local and metastatic
locations can affect the functionalities of immune mediators (Lee and Gujar,
2018).
Something different to research for would be changing T cell response
with a cytokine-expressing oncolytic virus. There are different types of T cell
populations that can targeted by viral therapy such as T regular and T effector
cells. T regular cells have been studied quite a lot regarding oncolytic viral
therapy. They are responsible for creating an immune-suppressing environment.
For example, HSV expresses IL-12 which was used in a glioma model by Cheema
et al. in 2013. It was concluded that the virus decreased the T regular cells and
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increases chances of survival. Due to this success, there should be research in this
area in the future.
Additionally, cytotoxic T lymphocytes (CTLs) improve the antitumor
immune environment, and with the increase in CTLs in the tumor
microenvironment, there is improved patient survival. Oncolytic viruses can help
recruit more CTLs into the tumor microenvironment, therefore, more research
into cytokine-expressing viruses used to enhance CTL recruitment and activation
can result in a promising future (Pearl, Markert, Cassady, Ghonime, 2019).
There are other oncolytic viruses such as the reovirus which is naturally
occurring, and it has been gaining more attention recently. Reovirus oncolysis
happens by the apoptosis mechanism along with autophagy. In HCV-associated
hepatocellular carcinoma, reovirus has helped with inducing a pro-inflammatory
response which suppresses the replication of HCV in host cells. More research in
other kinds of oncolytic viruses will help with cancer immunotherapy.
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IV.

Conclusion
Oncolytic virus therapy has shown to have a positive effect in cancer
immunotherapy, and its role in presenting antitumor effects is highly important. The
efficacy of oncolytic virus therapy is predicted to improve in the future, in addition to
immunotherapy. This is the beginning of a new era of cancer treatment, where patients
can choose to go for oncolytic virus therapy. With more research in oncolytic viruses,
there can be a promising future in cancer immunotherapy.
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